SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-037819
Filing Date
2024-09-23
Accepted
2024-09-23 16:31:17
Documents
13
Period of Report
2024-09-20
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37936
  Complete submission text file 0001493152-24-037819.txt   213701

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tnfa-20240920.xsd EX-101.SCH 3018
3 XBRL LABEL FILE tnfa-20240920_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tnfa-20240920_pre.xml EX-101.PRE 24167
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3697
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 241316581
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)